| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.27 | 4e-11 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.24 | 5e-10 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-08 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.28 | 1e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.35 | 2e-07 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.26 | 8e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 1e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.31 | 1e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.18 | 5e-06 |